The Daikyo Crystal Zenith Insert Needle Syringe System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

The Daikyo Crystal Zenith Insert Needle Syringe System


The Daikyo Crystal Zenith® Insert Needle Syringe System: A first-in-class, prefillable syringe solution for drug administration

Protect your drug product’s integrity with the industry’s first adhesive- and tungsten-free insert needle syringe system – the Daikyo Crystal Zenith Insert Needle Syringe System. Made from a break-resistant cyclic olefin polymer, the insert needle design minimizes potential contamination and product waste due to manufacturing and performance issues associated with traditional glass and staked-needle syringe systems.

The syringe barrel and piston are silicone-oil-free to help maximize purity and reduce risk. The piston with Daikyo Flurotec® barrier film helps minimize the effect of extractables and leachables. Flurotec barrier film also provides superior functional performance without the addition of silicone oil for lubricity. The syringe system is provided sterile and ready-to-fill in a package designed to be compatible with existing filling technologies.

The break-resistant system offers a variety of benefits that maximize value, enhance delivery and minimize risk, including:

  • Designed to maximize stability, purity and efficacy of your drug product
  • Manufactured to exacting standards in a clean room environment
  • 100% vision inspection
  • Potential to reduce protein aggregation caused by packaging materials
  • Excellent glass-like transparency
  • Suitable for high-viscosity products and those requiring low-temperature storage
  • Designed to be compatible with auto-injectors
  • Custom design and molding capabilities provide the flexibility to develop innovative new systems

 

West Pharmaceutical Services, Inc.
Email: westpharmaceuticalservices@westpharma.com
Website: www.westpharma.com

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
29%
Oversee medical treatment of patients in the US.
10%
Provide treatment for patients globally.
6%
All of the above.
42%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?

Click here